Indication

Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections.

Medicine details

Medicine name:
delafloxacin (Quofenix)
SMC ID:
SMC2453
Pharmaceutical company
Menarini Pharmaceuticals UK
BNF chapter
Infections
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
02 May 2022